Yabing Guo
Overview
Explore the profile of Yabing Guo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, et al.
Lancet
. 2025 Jan;
405(10474):203-215.
PMID: 39798578
Background: Transarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and pembrolizumab to TACE versus dual placebo plus TACE in...
2.
Xiong J, Ouyang W, Yang M, Gao Z, Zhou H, Lou H, et al.
Adv Ther
. 2024 Sep;
41(11):4153-4171.
PMID: 39276185
Introduction: Iparomlimab (QL1604) is a humanized immunoglobulin G4 mAb against programmed cell death protein 1 (PD-1). Here, we report the preliminary efficacy, safety, pharmacokinetics, and immunogenicity of iparomlimab in patients...
3.
Li J, Bai Y, Chen Z, Ying J, Guo Y, Fang W, et al.
Cancer Immunol Immunother
. 2024 Sep;
73(11):219.
PMID: 39235596
Background: Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MER), VEGFR-2, KIT, and MET. SAFFRON-104 (NCT03941873) was a multicohort phase Ib/II study investigating sitravatinib with/without tislelizumab, an...
4.
Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H, et al.
BMC Med
. 2024 Apr;
22(1):172.
PMID: 38650037
Background: Lenvatinib is widely used in treatment of unresectable hepatocellular carcinoma (uHCC), but the benefit of its combination with immunotherapy needs to be verified. This study evaluated the efficacy and...
5.
Wang K, Cui H, Zhu Y, Hu X, Hong C, Guo Y, et al.
BMC Cancer
. 2024 Feb;
24(1):246.
PMID: 38388861
Background: Artificial intelligence (AI)-assisted clinical trial screening is a promising prospect, although previous matching systems were developed in English, and relevant studies have only been conducted in Western countries. Therefore,...
6.
Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, et al.
Liver Cancer
. 2023 Oct;
12(5):405-444.
PMID: 37901768
Background: Primary liver cancer, of which around 75-85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a...
7.
Qin S, Kudo M, Meyer T, Bai Y, Guo Y, Meng Z, et al.
JAMA Oncol
. 2023 Oct;
9(12):1651-1659.
PMID: 37796513
Importance: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and additional first-line treatments are needed. The programmed cell death protein 1 inhibitor tislelizumab demonstrated efficacy and a tolerable...
8.
Qin S, Chan S, Gu S, Bai Y, Ren Z, Lin X, et al.
Lancet
. 2023 Jul;
402(10408):1133-1146.
PMID: 37499670
Background: Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-angiogenic therapy alone in advanced solid tumours, but not...
9.
Guo Y, Tian G, Chen X, Hou Y, Zhang X, Xue X, et al.
Exp Cell Res
. 2023 Feb;
425(1):113521.
PMID: 36841325
Liver fibrosis is a wound-healing response that arises from various aetiologies. Flavonoid compounds have been proved of their anti-liver fibrosis effects. This study aimed to elucidate the protective effect and...
10.
Shao G, Bai Y, Yuan X, Chen X, Gu S, Gu K, et al.
EClinicalMedicine
. 2022 Oct;
54:101679.
PMID: 36247923
Background: In the global REACH-2 study, ramucirumab significantly improved overall survival (OS) compared with placebo in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP). REACH-2 China study aimed...